Introduction
[Fe]-hydrogenase, also known as H 2 -forming methylenetetrahydromethanopterin (methylene-H 4 MPT) dehydrogenase (Hmd), is one of three known hydrogenases [1] [2] [3] [4] [5] . Hmd is involved in the methanogenic pathway of many hydrogenotrophic methanogenic archaea and reversibly catalyzes the stereoselective hydrogenation of methenyl-H 4 MPT + to methylene-H 4 MPT using H 2 as a hydride donor (Fig. 1A) [6, 7] .
Hmd occurs as a homodimer consisting of a central globular unit (termed C-unit) formed by the C-terminal domains of each subunit and two N-terminal Rossmann-like domains (termed N-unit). Hmd was found in an 'open' or 'closed' conformation [3] , defined by the orientation of the C-and N-units relative to each other. The active site is located between them and the open-to-close transition is considered to play a crucial role in the catalytic cycle [2, 6] . Each N-unit of Hmd harbors one iron-guanylylpyridinol (FeGP) cofactor as a prosthetic group (Fig. 1B) [4, 8] . The iron center is coordinated by two cis-CO, one cysteine-thiolate, one solvent, and the pyridinol-nitrogen and the acyl-carbon of the guanylylpyridinol ligand [9] [10] [11] [12] [13] . Based on the X-ray crystal structure of Hmd complexed with isocyanide inhibitors, the solvent-binding site of the organometallic iron-carbonyl complex has been proposed to serve as the H 2 -binding site [14, 15] . The FeGP cofactor can be extracted from the Hmd holoenzyme (holo-Hmd) [13, 16] and subsequently used to reconstitute a fully active holo-Hmd from an Hmd apoenzyme (apo-Hmd). The X-ray structure of the reconstituted holo-Hmd of Methanocaldococcus jannaschii revealed binding of the intact FeGP cofactor [1, 2, 4] .
The genomes of many hydrogenotrophic methanogenic archaea harbor genes related to the hmd gene. The encoding proteins HmdII and HmdIII have 20-30% amino acid sequence identity with Hmd [17] ; those of M. jannaschii (HmdII, MJ1338 and HmdIII, MJ0715) show~20% identity to Hmd (MJ0784) [18] . Some hydrogenotrophic methanogens, e.g. Methanococcus voltae (US DOE Joint Genome Institute, Walnut Creek, CA, USA) and Methanobrevibacter smithii [19] , have an hmd gene and produce active Hmd [20] but their genomes do not harbor genes encoding HmdII and HmdIII. The hmdII gene has been recently identified in the genome of the hyperthermophilic bacterium Desulfurobacterium thermolithotrophum, but this non-methanogen lacks the hmd gene [21] .
HmdII and HmdIII from various methanogens have a sequence identity of~60-80% relative to each other (those from M. jannaschii 65%), which indicates that HmdII and HmdIII have similar structures and functions. After their identification in genomes, HmdII and HmdIII were tentatively considered as Hmd homologs that catalyze the same reaction as Hmd [22] . Later on, preliminary data suggested that HmdII can bind the FeGP cofactor [23, 24] ; however, neither HmdII nor HmdIII have been reconstituted with the FeGP cofactor and kinetically analyzed. Therefore, their function remains elusive.
Here, we present the reconstitution of the HmdII holoenzyme (holo-HmdII) from the HmdII apoenzyme (apo-HmdII) and the FeGP cofactor, its infrared spectroscopic characterization, kinetic studies and X-ray structure analysis of the apo-HmdII, holo-HmdII and apo-HmdII with bound methylene-H 4 MPT. Based on the obtained results, we discuss potential functions of the Hmd-related proteins. Fig [7] .
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Results
Infrared analysis of holo-HmdII
In the infrared spectrum of holo-HmdII, the peaks of the antisymmetric and symmetric stretching band of the iron-ligating CO were split and have frequencies of 2015 + 1994 cm À1 and 1946 + 1930 cm À1 , respectively (Fig. 2) . These frequencies resembled those of holo-Hmd (2011 and 1944 cm À1 ), which is indicative of similar environments for the iron complexes. The peak splitting argued for at least two distinct FeGP-binding modes. Addition of methylene-H 4 MPT to the holo-HmdII solution resulted in a minor frequency shift and a substantial intensity change of the CO bands ( Fig. 2) . Moreover, the CO peaks are sharper in holo-HmdII than in holo-Hmd, implying that the CO ligands are more encapsulated after binding methylene-H 4 MPT. By contrast, methenyl-H 4 MPT + changed the infrared spectrum of holo-HmdII only slightly, but appears also to bind in the vicinity of the CO ligands. The greater influence of methylene-H 4 MPT on the environment of CO might reflect larger conformational changes of the protein.
X-Ray structure analysis of HmdII of Methanocaldococcus jannaschii
Overall structure
The crystal structures of apo-HmdII and reconstituted holo-HmdII from M. jannaschii have been determined at 1.9 and 2.2 A resolution, respectively, using the Se-methionine-based multiple anomalous dispersion method for initial phase determination. The structures of apo-HmdII and reconstituted holo-HmdII are almost identical. Like Hmd, HmdII is a homodimer composed of a C-unit formed by the intertwined C-terminal segments (residues 205-355) of the two subunits and two N-units both binding one FeGP cofactor (residues 1-204) [3] . Despite related global architectures reflected in an rmsd of 2.9
A (271 of 353 residues), HmdII and Hmd reveal remarkable structural changes ( Fig. 3A ,B) of potential functional relevance.
The structure of the loop region after the strand 13 : 17 directly involved in the FeGP cofactor binding is largely conserved, but adjacent regions that pack against it as the two-helical segment (residues [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] and the helical region (residues 68-115) of Hmd are truncated in HmdII. Apparently, the FeGP cofactor binding site is more loosely anchored with the rest of the protein in HmdII than in Hmd.
The C terminus of each subunit is prolonged in HmdII by~50 residues (residues 302-353) compared with Hmd. This dominantly helical segment increases not only the interface between the C-terminal segments of both subunits, but also the interface between the Cand N-units. Helix 336 : 351 contacts helix 131 : 140, and residues 315-319 the loop after strand 167 : 171, whose prolongation of nine residues in HmdII affords this contact. Consequently, the transition between open and closed states, as postulated for Hmd [2, 3, 25] might be impaired in HmdII. In addition, the rigidbody movement of the N-unit relative to the C-unit is much smaller between apo-and holo-HmdII than between apo-and holo-Hmd. In principle, this finding supports the limited open-to-close capabilities but might also be triggered by crystal lattice effects. Interestingly, the conformation of apo-and holo-HmdII structures rather resembles that of the closed apo-Hmd.
We analyzed the charge distribution of the surface of HmdII and Hmd to determine differences between them for identifying potential binding sites for other proteins present in HmdII, but not in Hmd. However, no attractive hot spot on the HmdII surface could be identified. A positively charged patch was detectable around the binding site of the FeGP cofactor in apo-Hmd and even more extended in apo-HmdII (data not shown), which was partly neutralized after FeGP binding.
Binding of the FeGP cofactor
FeGP cofactor is bound in holo-HmdII at the same position and in a related conformation as in holo-Hmd ( Fig. 3C,D) . Several cofactor-protein interactions, i.e. Cys127 to Fe as well as Asp86 and Glu61 (HmdII nomenclature) to guanosine, conserved between HmdII and Hmd argue for HmdII as a natural FeGP cofactor binding protein. Nevertheless, notable differences exist. The pyridinol ring is sandwiched between Phe99 and Phe102 in HmdII and by the more polar Trp148 and Lys151 in Hmd. Trp148 forms, in addition, a hydrogen bond to the phosphate group of the FeGP cofactor, which is compensated by a hydrogen bond with Tyr25 in HmdII. Tyr25 is replaced by His14 in Hmd, which possibly serves as an acceptor for the proton released after heterolytic cleavage of H 2 ; substitution of His14 with alanine in Hmd leads to a dramatic decrease in enzymatic activity [2, 4] .
Methylene-H 4 MPT binding to apo-HmdII
Crystals of apo-HmdII were soaked with methenyl-H 4 MPT + and methylene-H 4 MPT and their structures were determined by the molecular replacement method ( Table 1) . In contrast to methenyl-H 4 MPT + , methylene-H 4 MPT could be bound to apo-HmdII with a high occupancy. Extra electron density interpretable as methylene-H 4 MPT was clearly visible in the active site cleft next to Cys127, a ligand of the FeGP cofactor iron in holo-HmdII ( Fig. 4 ). Its conformation resembles that of methylene-H 4 MPT bound to holo-Hmd C176A (PDB code 3H65) ( Fig. 4D) [2] . In both Hmd and HmdII, the electron density of methenyl-H 4 MPT after the benzyl group is weak and beyond the ribose group is largely blurred [2] . In HmdII, the pterin ring of methylene-H 4 MPT of apo-HmdII forms polar interactions with Ala212, Ser216 and Ser279, the latter residue originates from the counter monomer ( Fig. 4C ). In addition, methylene-H 4 MPT is flanked by several nonpolar and well-distributed residues including Leu24, Tyr25, Val159, Met214, Ile237, Ala239, Met243 and Met283, suggesting that its binding to HmdII has a biological function. Moreover, methylene-H 4 MPT has many more contacts with the polypeptide in the closed apo-HmdII than in the open holo-Hmd C176A structures ( Fig. 4D ). Despite various attempts, crystals of the holo-HmdII-methenyl-H 4 MPT + or the holo-HmdIImethylene-H 4 MPT complexes were not obtained. To analyze the arrangement of the FeGP cofactor relative to methylene-H 4 MPT, apo-HmdII with bound methylene-H 4 MPT and holo-HmdII were superimposed. In the resulting model, the C14a atom of methylene-H 4 MPT is placed 2.4
A from the iron site of the FeGP cofactor ( Fig. 4E ). Only small rearrangements in the holo-HmdII-methylene-H 4 MPT complex are required to provide enough space for H 2 binding and an optimal active site geometry. The obtained FeGP cofactor-methylene-H 4 MPT geometry is similar to that proposed for Hmd modeled from the open holo-Hmd C176A-methylene-H 4 MPT complex and the apo-Hmd structure (Fig. 4E,F) [2] . The same catalytic capabilities for HmdII and Hmd appear to be conceivable.
Activity assays of holo-HmdII
The recombinantly produced, pure and successfully reconstituted holo-HmdII now allowed serious kinetic studies to find out its catalytic activity. To probe Hmd-like reactions, we assayed the oxidation of methylene-H 4 MPT and methylene-tetrahydrofolate (tetrahydrofolate is an analog of H 4 MPT), and the reduction of methenyl-H 4 MPT + and methenyl-tetrahydrofolate with H 2 both at 40°C under the conditions described in the Materials and Methods. Despite repeated attempts using different preparations, we could not detect any catalytic activity of holo-HmdII. Following the proposal of Reeve et al. [22] , we also tried to measure the reduction of methylene-H 4 MPT with H 2 to methyl-H 4 MPT. Again, no catalytic activity was found. With the aim of recovering the Hmd activity, an exchange of Tyr25 of HmdII with a histidine was performed because the histidine at this position in Hmd was considered as a proton acceptor after H 2 cleavage [2] . However, the Tyr25His HmdII variant was catalytically inactive. Previous UV/vis and CD spectroscopic measurements indicated that Hmd with bound methenyl-H 4 MPT + can reversibly accept hydride from H 2 and produce methylene-H 4 MPT under single turnover conditions at pH 6.0 [25] . To probe the single turnover Hmd reaction of holo-HmdII at the same conditions, we used equimolar concentrations (0.1 mM) of enzyme and substrate, but could not detect any activity (data not shown).
Discussion
Over the years, several functional studies on HmdII and HmdIII have been performed. The hmdII and hmdIII genes are upregulated at low and high concentrations of H 2 , respectively [22] when expressed in Methanothermobacter thermautotrophicus cells grown under laboratory conditions. Likewise, expression of hmdII in Methanococcus maripaludis is upregulated under syntrophic growth conditions [26] . The amounts of HmdII and HmdIII in Methanothermobacter marburgensis grown under normal conditions are 1% and < 0.1%, respectively, of the soluble proteins in the cell extract based on western blotting [27] . Binding of the FeGP cofactor was predicted by homology models [28] and inhibition of the holoenzyme reconstitution with apo-HmdII [23, 24] . HmdII and HmdIII of M. jannaschii binds to proyl-tRNA synthetase and tRNA inferred from the copurification of HmdII from cell extracts with prolyl-tRNA synthetase [29, 30] and in vitro binding studies [31] . Based on this information, various functions for the Hmd-related proteins have been considered: (a) catalytic Hmd isoenzyme [22] , (b) H 2 sensor [27] , (c) scaffold protein involved in FeGP cofactor biosynthesis [24, 28] , (d) storage protein for the FeGP cofactor [24, 28] , and (e) regulation of protein biosynthesis due to the interactions with aminoacyl-tRNA synthetase and tRNA [29] [30] [31] .
The potential functions for HmdII and HmdIII are predicted based on primary structures, modeled tertiary structures, heterologously produced apoenzymes or cell extracts. The provided pure apo-and holo-HmdII allow a detailed structural and kinetic analysis and open new perspectives for functional studies. Holo-HmdII did not exhibit any catalytic activities with H 4 MPT and tetrahydrofolate derivatives and/or H 2 as substrates, despite similar FeGP cofactor and methylene-H 4 MPT-binding properties and active site geometries in HmdII and Hmd. A more careful structural inspections reveals two features that rationalizes these findings: (a) the increased interface between N-and C-units, mainly due to a C-terminally prolonged polypeptide chain, impairs the mobility between them which is required for the catalytic cycle of Hmd; and (b) the exchange of a histidine in Hmd to a tyrosine in HmdII. The histidine is most likely involved in proton transfer from buried H 2 to bulk solvent in Hmd [2] . Thus, HmdII is not an isoenzyme or homolog of Hmd but a paralog. We can, of course, not exclude that HmdII uses completely different compounds as substrates but the unambiguous binding of the FeGP cofactor and methylene-H 4 MPT does not favor this possibility.
A possible H 2 -sensor function of HmdII could be ruled out due to the performed single turnover hydride transfer assays, which exhibited no activity. A single turnover event would be still achievable in the absence of a specific proton uptake and an open-to-closed transition.
Because some methanogenic archaea lack the genes for Hmd paralogs, but still produce active Hmd [20, 32] and because hmdII gene-deletion experiments with Methanococcus maripaludis had no impact on the biosynthesis of the FeGP cofactor [33] , a scaffold function for the cofactor biosynthesis can also be ruled out. The affinity between HmdII and methylene-H 4 MPT is also not compatible with this idea. The latter argument also makes a storage function of HmdII for the FeGP cofactor unlikely.
The only plausible hypothesis remains a function of HmdII as a regulatory protein in protein synthesis based on the previously found binding of holo-HmdII to aminoacyl-tRNA synthetase and tRNA [29] [30] [31] . According to infrared spectroscopic data, HmdII can distinguish between methenyl-H 4 MPT + and methylene-H 4 MPT, and binding of the latter induces marked conformational changes around the Fe complex. Therefore, we suggest that HmdII senses the intracellular methylene-H 4 MPT concentration, implying that the postulated conformational changes upon methylene-H 4 MPT binding alters the affinity of HmdII to potential cellular binding proteins or nucleic acids. Preliminary comparative surface profile analyses of HmdII and Hmd of M. jannaschii and protein-docking calculations of HmdII and prolyl-tRNA synthetase from M. jannaschii (PDB code: 1NJ8) [34] , inconclusive to date, cannot replace future experimental studies. The impact of methylene-H 4 MPT on interactions between holo-HmdII and aminoacyl-tRNA synthetases and tRNA (or nucleic acids) has to be biochemically explored. From the perspective of the hydrogenotrophic methanogen, a strict control of protein synthesis under H 2 -limiting conditions by the amount of reducing equivalents is beneficial as proposed previously [22] . Methylene-H 4 MPT is a metabolite produced in the midst of the methanogenic pathway, and a regulation of protein synthesis by its intracellular concentration would satisfy this need.
We have previously successfully predicted the catalytic function of several proteins based on the crystal structure and on subsequent in vitro activity studies for verification (structure-to-function approach) [35, 36] . In this study, structural together with infrared spectroscopic and kinetic data clearly excluded most of the postulated functions of HmdII and we present a hypothesis about its cellular role of methylene-H 4 MPT sensor. This hypothesis is consistent with the available data and experimentally verifiable in future on the basis of the established protocol for preparing pure holo-HmdII. This study teaches us that a functional annotation exclusively based on sequence or even convincing structural data still requires a direct experimental validation. Despite similar overall structures, potentially identical prosthetic groups and substrates as well as active site geometries, HmdII is not an Hmd isoenzyme.
Materials and methods
Materials
All chemicals were used without further purification. Poly (ethylene glycol) 300, nickel sulfate, 3-(2-pyridyl)-5,6-di(2furyl)-1,2,4-triazine-5 0 5 00 -disulfonic acid disodium salt (Ferene), and potassium hydroxide were purchased from Sigma-Aldrich (Taufkirchen, Germany). L-Selemomethionine (SeMet) was purchased from Acros Organics (Geel, Belgium). Magnesium chloride, 32% ammonia solution, poly(ethylene glycol) 200 and thiamine were purchased from Merck (Darmstadt, Germany). The following reagents were obtained from Roth (Karlsruhe, Germany): methanol, kanamycin sulfate, ampicillin sodium salt, Mops, imidazole, ammonium chloride, L-methionine, sodium chloride, sodium dihydrogen phosphate, disodium hydrogen phosphate, hydrochloric acid, potassium chloride, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, D-glucose and FeCl 3 Á6H 2 O. Isopropyl b-D-thiogalactopyranoside was purchased from Fermentas (St. Leon-Rot, Germany).
The FeGP cofactor was isolated from holo-Hmd from Methanothermobacter marburgensis [16] . Apo-Hmd was purified from recombinant Eschericha coli BL21(DE3) harboring an expression vector, as described previously [8, 16] . The expression plasmid with the M. jannaschii hmdII gene in pET22b (Novagen, Darmstadt, Germany) at its NdeI-BamHI sites was a kind gift of Y.M. Hou [29] . The M. jannaschii hmdII Y25H mutant gene with codon optimization for Escherichia coli host cells was purchased from Gen-Script USA Inc. (Piscataway, NJ, USA) as hmdII Y25H-pET24b (Novagen). Methenyl-H 4 MPT + and methylene-H 4 MPT were prepared, as reported previously [37] . (6R,S) -5,10-methenyl-5,6,7,8-tetrahydrofolic acid chloride and (6R,S) -5,10-methylene-5,6,7,8-tetrahydrofolic acid calcium salt were purchased from Schircks Laboratories (Jona, Switzerland).
Amino acid sequences were aligned using CLUSTAL W2 [38] . The figure of the alignment was generated using ESPRIPT3 [39] .
Heterologous production and purification of HmdII
Escherichia coli BL21 (DE3) cells were transformed with the expression plasmid containing M. jannaschii apo-HmdII with a C-terminal His 6 tag and grown at 37°C in Luria-Bertani medium supplemented with 100 lgÁmL À1 ampicillin to an optical density 600 (OD600) = 1.0. Protein expression was induced by the addition of 1 mM isopropyl b-Dthiogalactopyranoside. After incubation for 4-6 h the cells were harvested by centrifugation and stored at À80°C before further use. The apo-HmdII Y25H mutant was produced in the same way as apo-HmdII using 50 lgÁmL À1 kanamycin instead of 100 lgÁmL À1 ampicillin. All procedures for the purification of apo-HmdII and the apo-HmdII Y25H mutant were performed on ice or at 4°C. The frozen cells containing apo-HmdII and the apo-HmdII Y25H mutant were resus- For the SeMet-labeled apo-HmdII preparation, E. coli B834 (DE3) (Novagen) cells transformed with the expression vector carrying the hmdII gene were cultured in M9 medium supplemented with 2.5 mM MgSO 4 , 2% (w/v) D-glucose, 0.01% (w/v) thiamine, 0.025 mM FeCl 3 , 50 lgÁmL À1 L-selenomethionine, and 100 lgÁmL À1 ampicillin at 37°C to an OD600 = 0.5 before induction of expression with 1 mM isopropyl b-Dthiogalactopyranoside as described above. SeMet-apo-HmdII was purified as described for apo-HmdII.
Reconstitution of the holoenzymes
To reconstitute the holoenzymes, apo-HmdII and apo-Hm-dII Y25H mutant were mixed with the FeGP cofactor under a N 2 /H 2 (95%/5%) atmosphere at 8°C in an anaerobic chamber (Coy Laboratories, Grass Lake, MI, USA) under red or yellow light [16] . The buffers of purified apo-HmdII and apo-HmdII Y25H mutant were exchanged with anoxic 10 mM Mops/KOH (pH 7.0) buffer containing 1 mM dithiothreitol using a PD-10 column (GE Healthcare). Apo-HmdII and the apo-HmdII Y25H mutant were then incubated with at least 1.5 eq. of the FeGP cofactor in 0.1 M Tris/HCl buffer pH 8.0 for 1 h at 8°C under anoxic conditions. The mixture of apo-HmdII and apo-HmdII Y25H mutant with FeGP cofactor was loaded onto a PD-10 column equilibrated with 10 mM Mops/KOH buffer containing 1 mM dithiothreitol (pH 7.0) to separate HmdII and the apo-HmdII Y25H mutant both reconstituted with FeGP cofactor from unbound FeGP cofactor.
Infrared spectroscopy
Attenuated total reflection-infrared spectra were recorded using a Bruker VERTEX 70V FTIR spectrometer equipped with an MCT detector. Attenuated total reflection optical configuration (DuraSampleIR TM , Sensir Technologies, Watford, UK) was employed with a silicon prism. The measurements were handled under red light to avoid photoinduced decomposition of the FeGP cofactor in the samples. Infrared spectra were continuously recorded with averaging of 512 scans at 4 cm À1 resolution under an argon stream; the sample was gradually concentrated on the optical element of the attenuated total reflection unit due to an evaporation of the water solute. The spectrum was chosen when the sample concentration was sufficiently high to resolve the CO band from the FeGP cofactor; the water band was subtracted and the spectrum was baseline corrected.
Crystallization
All proteins were crystallized at 8°C using the sitting drop vapor diffusion method. A 1 lL aliquot of apo-HmdII (12 mgÁmL À1 ) in 50 mM potassium phosphate buffer (pH 7.0) with 0.3 M KCl was mixed with 1 lL of a reservoir solution composed of 40% (v/v) poly(ethylene glycol) 300 and 100 mM phosphate-citrate buffer (pH 4.2); crystals appeared within 1 week. Crystals of SeMet-apo-HmdII were obtained within 1 week when adding a 1 lL aliquot of SeMet-apo-HmdII (20 mgÁmL À1 ) in 10 
X-ray data collection and refinement
Crystals of apo-HmdII, SeMet-apo-HmdII, HmdII reconstituted with the FeGP cofactor and SeMet-apo-HmdII incubated with various ligands were frozen under a cryostream of N 2 at 100 K without adding a cryoprotectant. Diffraction data were collected at 100 K on beamline X10SA equipped with a PILATUS 6M detector at the Swiss Light Source (Villigen, Switzerland). Data were processed using XDS [40] . To determine the crystal structure of apo-HmdII, multiple anomalous dispersion data were measured at the selenium edge of the SeMet-apo-HmdII crystals. Selenium atom sites were detected with SHELX C/D [41] . Phases were determined using the program SHARP and improved by the solvent flattening procedure of SOLOMON implemented in SHARP [42] . Automated model building was performed using ARP/WARP [43] . The SeMet-apo-HmdII model was manually completed and refined using COOT [44] , REFMAC5 [45] and PHENIX [46] . Crystal structures of other crystal forms of HmdII were solved by molecular replacement with MOLREP [47] or PHASER [48] using the SeMet-apo-HmdII structure as a search model. The TLS option was used for all structures in the final stage of refinement [49] . The final models were validated using MOLPROBITY [50] . The resulting structures were established at a resolution of 1.7
A for apo-HmdII, 1.9 A for SeMet-apo-HmdII, 2.2 A for holo-HmdII, 1.9
A for methylene-H 4 MPT-bound SeMetapo-HmdII, and 1.9
A for methenyl-H 4 MPT + -bound SeMet-apo-HmdII. Data collection and refinement statistics are summarized in Table 1 . Atomic coordinates and structure factors are available in the Protein Data Bank (www.pdb.org) under the accession numbers; 4YT8 for SeMet-labeled apo-HmdII; 4YT2 for apo-HmdII; 4YT4 for holo-HmdII; 4YT5 for apo-HmdII with bound methylene-H 4 MPT. Crystal structures were superimposed using DALILITE [51] or SUPERPOSE [52] in CCP4 [53] . Charge distributions on the surfaces of the structures were calculated by PYMOL (v. 1.3r1, Schr€ odinger, LLC). Figures 3 and 4 were generated by PYMOL (v. 1.3r1, Schr€ odinger, LLC).
Enzyme activity assay
To assay the conversion of methenyl-H 4 MPT + to methylene-H 4 MPT, holo-HmdII or the holo-HmdII Y25H mutant was added to 20lM methenyl-H 4 MPT + in 120 mM potassium phosphate buffer (pH 7.5) in a 1-cm-path quartz cuvette under 100% H 2 at 40°C. To assay Hmd-catalyzed conversion of methylene-H 4 MPT to methenyl-H 4 MPT + , holo-HmdII or the holo-HmdII Y25H mutant was added to 20lM methylene-H 4 MPT in 120 mM potassium phosphate buffer (pH 6.0) inside a 0.3-cm-path quartz cuvette under 100% N 2 . Methenyl-tetrahydrofolate and methylenetetrahydrofolate were tested as the Hmd-catalyzed reactions described above. The change in absorbance at 336 nm was monitored. For the activity under single-turn-over conditions, UV/vis spectra of 0.1 mM HmdII in 50 mM Mes/ NaOH (pH 6.0) in the presence of 0.1 mM methenyl-H 4 MPT + under N 2 , and H 2 were measured as described previously [25] .
